<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900536</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-RE05-TRANSORCE</org_study_id>
    <secondary_id>CDR0000601175</secondary_id>
    <secondary_id>EU-20867</secondary_id>
    <secondary_id>EUDRACT-2006-006079-19</secondary_id>
    <secondary_id>ISRCTN38934710</secondary_id>
    <nct_id>NCT00900536</nct_id>
  </id_info>
  <brief_title>DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE</brief_title>
  <official_title>TRANSORCE (A Sub-study of SORCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with&#xD;
      kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA&#xD;
      and identify biomarkers related to cancer. It may also help doctors predict how well patients&#xD;
      will respond to sorafenib.&#xD;
&#xD;
      PURPOSE: This research study is looking at the DNA in blood and/or tissue samples from&#xD;
      patients with primary kidney cancer receiving sorafenib on clinical trial MRC-RE05-SORCE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Examine the relationship between tumor genotype, expression, and patient outcome.&#xD;
&#xD;
        -  Examine the relationship between constitutional genotype and patient outcome.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo blood and/or tissue sample collection for laboratory studies. Laboratory&#xD;
      studies include generation of tissue microarrays; analysis of protein expression by&#xD;
      immunohistochemistry; tumor DNA extraction and whole genome amplification; detection of VHL&#xD;
      or other relevant gene mutations by direct sequencing; and constitutional (lymphocyte DNA)&#xD;
      genotyping by single nucleotide polymorphism analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Relationship between tumor genotype, expression, and patient outcome</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship between constitutional genotype and patient outcome</measure>
  </primary_outcome>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed resected renal cell carcinoma&#xD;
&#xD;
               -  Clear cell or non-clear cell tumor&#xD;
&#xD;
          -  Receiving sorafenib tosylate on clinical trial MRC-RE05-SORCE&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Eisen</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>stage I renal cell cancer</keyword>
  <keyword>stage II renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>papillary renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

